LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Abierto

Sector Salud

75.74 0.41

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

75.02

Máximo

76.5

Métricas clave
By Trading Economics
Ingresos	-973K -16M
Ventas	17M 161M
BPA	-0.16
Margen de beneficio	-10.05
Empleados	610
EBITDA	-6.8M -28M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+27.93 upside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-335M 7.1B
Apertura anterior	75.33
Cierre anterior	75.74

Noticias sobre sentimiento de mercado

By Acuity

75%

25%

321 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

73 / 75.85 Soporte y Resistencia

Intra-Cellular Therapies Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 sept 2024, 01:45 UTC

Ganancias

Preview -- Barron's

13 sept 2024, 20:03 UTC

Principales Noticias

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15 sept 2024, 23:47 UTC

Charlas de Mercado

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15 sept 2024, 23:03 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2024, 23:03 UTC

Charlas de Mercado

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15 sept 2024, 16:52 UTC

Principales Noticias

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15 sept 2024, 09:30 UTC

Principales Noticias

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15 sept 2024, 07:00 UTC

Principales Noticias

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14 sept 2024, 14:09 UTC

Principales Noticias

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14 sept 2024, 13:25 UTC

Principales Noticias

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14 sept 2024, 09:30 UTC

Principales Noticias

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14 sept 2024, 09:30 UTC

Principales Noticias

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14 sept 2024, 03:00 UTC

Principales Noticias

What Scared Ford's CEO in China -- WSJ

14 sept 2024, 03:00 UTC

Principales Noticias

What Scared Ford's CEO in China -- WSJ -2-

14 sept 2024, 00:01 UTC

Principales Noticias

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13 sept 2024, 21:14 UTC

Principales Noticias

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13 sept 2024, 21:06 UTC

Principales Noticias

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13 sept 2024, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

13 sept 2024, 20:47 UTC

Charlas de Mercado

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13 sept 2024, 20:44 UTC

Adquisiciones, fusiones, absorciones

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13 sept 2024, 20:41 UTC

Principales Noticias

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13 sept 2024, 20:31 UTC

Ganancias

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13 sept 2024, 20:13 UTC

Adquisiciones, fusiones, absorciones

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13 sept 2024, 20:10 UTC

Adquisiciones, fusiones, absorciones

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13 sept 2024, 20:02 UTC

Adquisiciones, fusiones, absorciones

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept 2024, 20:02 UTC

Adquisiciones, fusiones, absorciones

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept 2024, 19:44 UTC

Charlas de Mercado

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13 sept 2024, 19:20 UTC

Charlas de Mercado

Crude-Oil Futures End Week With Small Gains -- Market Talk

13 sept 2024, 19:09 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13 sept 2024, 18:01 UTC

Charlas de Mercado

Gold Analysts Call For New Leg Of Rally -- Market Talk

Comparación entre iguales

Cambio de precio

Intra-Cellular Therapies Inc Esperado

Precio Objetivo

By TipRanks

27.93% repunte

Estimación a 12 meses

Media 96.43 USD 27.93%

Máximo 130 USD

Mínimo 74 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Intra-Cellular Therapies Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para Intra-Cellular Therapies Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

73 / 75.85Soporte y Resistencia

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Sentimiento

By Acuity

321 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.